Pricing Log in Create free account
Friday 6 November 2026 Export KNSA’s income statement to Excel — free account

Kiniksa Pharmaceuticals International, plc

KNSA Healthcare Drug Manufacturers Specialty & Generic

Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024.

Revenue
+58.1%
EPS
+142.2%
Free cash flow
+43.5%

Quarter to September 2026, against a year earlier

88.50 7.62 −7.93%
Market cap
$6.9B
P/E
62.1×
Fwd P/E
67.8×
Dividend yield
—
F-score
8/9
Altman Z
10.35
Beneish M
−3.16
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Kiniksa Pharmaceuticals International, plc (KNSA) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, Kiniksa Pharmaceuticals International, plc (KNSA) trades at a EV/EBITDA of 48.0×. Over the past ten years it has ranged from 0.0× (June 2025) to 425× (September 2025); the current reading is higher than 89% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 12.2× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 33.6× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 66.6× —
FY2021 0.0× —

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 39.8× (8.48%)
Jun 2026 43.5× 28.24%
Mar 2026 33.9× 0.88%
Dec 2025 33.6× (47.75%)
18 more quarters

Against its own ten years

Low 0.0× High 425×
Ten-year median 0.0×
Current reading's percentile 89

EV/EBITDA against peers

Company EV/EBITDA
HIMS Hims & Hers Health, Inc. compare n/m
SUPN Indivior Pharmaceuticals Inc. compare 7.0×
AMRX AMNEAL PHARMACEUTICALS, INC. compare 14.3×
LNTH Lantheus Holdings, Inc. compare 16.7×
ELAN Elanco Animal Health Incorporated compare 19.7×
LQDA Liquidia Corporation compare 22.7×
RDY Dr. Reddy's Laboratories Ltd compare 22.9×
ALKS Alkermes plc compare 37.9×
KNSA Kiniksa Pharmaceuticals International, plc 48.0×
Drug Manufacturers Specialty & Generic industry median 12.2×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on KNSA